In vivo pig models of venous thrombosis mimicking human disease

Thrombosis and Haemostasis

Volumn 89, Issue 2, 2003, Pages 256-263

  Kang, Chantal ^a   Bonneau, Michel ^b   Brouland, Jean Philippe ^a   Dit Sollier, Claire Bal ^a   Drouet, Ludovic ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b CEMAGREF   (France)

Author keywords

Animal models; Deep venous thrombosis; Pig; Thrombus structure

Indexed keywords

ANTICOAGULANT AGENT; FIBRIN; PROCOAGULANT; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL; BLOOD VESSEL PROSTHESIS; CELL STRUCTURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ERYTHROCYTE; HYPERCOAGULABILITY; IN VIVO STUDY; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; STENOSIS; SWINE; THROMBOCYTE; THROMBOCYTE STRUCTURE; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0037329309     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613440     Document Type: Article

References (26)

1. Levi M, Dorffle-Melly J, Johnson GJ, Drouet L, Badimon L. Usefulness and limitations of animal models of venous thrombosis. Thromb Haemost 2001; 86 (5): 1331-3.
2. Arroyo JG, Dastgheib K, Hatchell DL. Antithrombotic effect of ticlodipine in an experimental model of retinal vein occlusion. Jpn J Ophthalmol 2001; 45 (4): 359-62.
3. Valji K, Bookstein JJ. Efficacy of adjunctive intrathrombotic heparin with pulse spray thrombolysis in rabbit inferior vena cava thrombosis. Invest Radiol 1992; 27 (11): 912-7.
4. Giedrojic J, Krupinski K, Breddin HK, Bielawiec M. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Pol J Pharmacol 1996; 48 (3): 317-22.
5. Raake W, Klauser RJ, Elling H, Zeiller P. Antithrombotic action of recombinant hirudin in a venous thrombosis model. Haemostasis 1991; 21 Suppl 1: 127-32.
6. Edwards S, Betz A, James H, Thompson E, Yonkovich S, Sinha U. Differences between human and rabbit coagulation factor X-implications for in vivo models of thrombosis. Thromb Res 2002; 106 (1): 71.
7. Wessler S. Studies in intravascular coagulation; Coagulation changes in isolated venous segments. J Clin Invest 1952; 31: 1011-4.
8. Millet J, Vaillot M, Theveniaux J, Brown NL. Experimental venous thrombosis induced by homologous serum in the rat. Thromb Res 1996; 81 (4): 497-502.
9. Bara L, Bloch MF, Samama MM. A comparative study of recombinant hirudin and standard heparin in the Wessler model. Thromb Res 1992; 68 (2): 167-74.
10. Prowse CV, Williams AE. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models. Thromb Haemost 1980; 44 (2): 81-6.
11. Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G et al. Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73 (4): 675-9.
12. Bacher P, Walenga JM, Iqbal O, Bajusz S, Breddin K, Fareed J. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. Thromb Res 1993; 71 (4): 251-63.
13. Roussi J, Andre P, Samama M, Pignaud G, Bonneau M, Laporte A et al. Platelet functions and haemostasis parameters in pigs: Absence of side effects of a procedure of general anaesthesia. Thromb Res 1996; 81 (3): 297-305.
14. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58 (4): 1078-84.
15. Ravanat C, Freund M, Dol F, Cadroy Y, Roussi J, Incardona F et al. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinolysis 1995; 6 (5): 446-55.
16. Didisheim P. Animal models useful in the study of thrombosis and antithrombotic agents. Prog Hemost Thromb 1972; 1: 165-97.
17. Aronson DL, Thomas DP. Experimental studies on venous thrombosis: Effect of coagulants, procoagulants and vessel contusion. Thromb Haemost 1985; 54 (4): 866-70.
18. Rizza CR. Haemostasis and blood coagulation. In: McGee JO, Isaacson PG, Wright NA, editors. Oxford Textbook of Pathology. Oxford University Press, Oxford, 1992: 502-9.
19. Lindop GBM, Percy-Robb IW, Walker ID. Disturbances of body fluids. Haemostasis and the flow of blood. In: MacSween RNM, Whaley K, editors. Muir's Textbook of Pathology. Arnold, London, 1992: 73-111.
20. Kroger K, Schelo C, Gocke C, Rudofsky G. Colour Doppler sonographic diagnosis of upper limb venous thromboses. Clin Sci (Lond) 1998; 94 (6): 657-61.
21. Kroger K, Fischer A, Hinrichs A, Gocke C, Rudofsky G. Patients with a malignant tumor have more extended thrombosis than patients without. Angiology 1998; 49 (11): 923-8.
22. Loud PA, Klippenstein DL. Lower extremity deep venous thrombosis in cancer patients: Correlation of presenting symptoms with venous sonographic findings. J Ultrasound Med 1998; 17 (11): 693-6.
23. Kazmers A, Groehm H, Meeker C. Acute calf vein thrombosis: Outcomes and implications. Am Surg 1999; 65 (12): 1124-7.
24. Ricci P, Cantisani V, Biancari F, Drud FM, Coniglio M, Di Filippo A et al. Contrast-enhanced color Doppler US in malignant portal vein thrombosis. Acta Radiol 2000; 41 (5): 470-3.
25. Carrie D, Caranobe C, Boneu B. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit. Br J Haematol 1993; 83 (4): 622-6.
26. Cadroy Y, Hanson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost 1993; 70 (4): 631-5.